There still lacks evidence to support the theory that proton-beam therapy is more effective than traditional therapy when it comes to treating prostate cancer; however, it would be hard to deduce that fact based on the rapidly growing popularity of proton therapy centers.
There still lacks evidence to support the theory that proton-beam therapy is more effective than traditional therapy when it comes to treating prostate cancer; however, it would be hard to deduce that fact based on the rapidly growing popularity of proton therapy centers.
Why would medical organizations want to take on such a costly technology? Because the machines also have the potential to bring in massive amounts of revenue. According to an article by Bloomberg Businessweek, these 500-ton machines — which are stored in “facilities that cost from $100 million to $200 million, and can require a football- field sized building to house” – can bring in as much as $50 million in revenue annually.
The only problem is that there lacks a body of evidence to support the use of proton-beam therapy as opposed to more traditional forms of therapy. According to Amitabh Chandra, a health economist at Harvard University’s John F. Kennedy School of Government, these proton therapy centers are “a metaphor for all the problems we have in American medicine” because of how they complicate the healthcare system. One commenter went as far as to say that this technology has “forced many doctors to become snake oil salesmen in an effort to pay for the equipment that there facility has bought into.”
The growing use of these types of costly technologies begs the question: Do the current pressures being placed on physicians under healthcare reform force them to look for other ways to supplement their practice revenue? More importantly, are these moves improving the quality of care delivered to their patients, or simply improving their bottom line? What are your thoughts?
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen